GlassScriptPhysician profile
Katia Y Hall
NPI 1366865842
$87,811.53
in general payments reported to CMS, 2019-2025
37 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,701 · 2022: $6,138 · 2023: $10K · 2024: $40K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $15K · Consulting Fee: $13K · Travel and Lodging: $10K · Education: $92.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,010.00 |
| Food and Beverage | $15,125.71 |
| Consulting Fee | $13,455.00 |
| Travel and Lodging | $10,289.86 |
| Education | $92.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $65,698.63 | 2021-2025 | Spravato, Invega Sustenna |
| Neuronetics, INC. | $8,370.89 | 2022-2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $2,731.61 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,251.46 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,178.79 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,012.36 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,000.17 | 2021-2025 | Caplyta |
| Alkermes, INC. | $960.91 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $709.74 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $655.32 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $645.76 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $637.97 | 2021-2024 | Rexulti |
| Corium, LLC | $322.17 | 2022-2024 | Azstarys |
| Almatica Pharma LLC | $313.43 | 2021-2024 | Gralise, Loreev Xr |
| Eisai INC. | $260.65 | 2021-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katia Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.